| Intro • Projets • Publications |

Formation

MD
MSc
FRCPC

Axe principal

Infectiologie et immunologie

Adresse

2705, boulevard Laurier, RC-709
Québec (Québec)
CANADA G1V 4G2

Téléphone

+1 418-525-4444, poste 42705

Télécopieur

+1 418-654-2715

Courriel

sylvie.trottier@crchul.ulaval.ca

Projet(s) de recherche reconnu(s) par l'Université Laval

Autre(s) projet(s) de recherche actif(s)

Publications récentes (voir toutes les publications de ce chercheur)

Routy J, Tremblay C, Angel J, Trottier B, Rouleau D, Baril J, Harris M, Trottier S, Singer J, Chomont N, Sekaly R, Boulassel M. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV medicine,  2012. Epub

Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Domingo MC, Giguere JF, Piret J, Mwatha A, Masse B, Bergeron MG. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. Contraception,  2010. 81: 79-85

Cornut G, Gagnon S, Hankins C, Money D, Pourreaux K, Franco EL, Coutlee F, Canadian Women's HIV Study Group. Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. Journal of medical virology,  2010. 82: 1168-78

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. The Journal of infectious diseases,  2009. 200: 973-83

Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Giguere JF, Domingo MC, Piret J, Tsague L, Zekeng L, Mwatha A, Masse B, Bergeron MG. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon. Contraception,  2009. 80: 484-92

Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. The New England journal of medicine,  2008. 359: 1442-55

Omar RF, Trottier S, Brousseau G, Lamarre A, Alexandre Gagnon, Bergeron MG. Distribution of a vaginal gel (Invisible Condom(R)) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study. Contraception,  2008. 77: 447-55

Fontaine J, Hankins C, Money D, Rachlis A, Pourreaux K, Ferenczy A, Canadian Women's HIV Study Group, Coutlee F. Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,  2008. 43: 307-12

Bodsworth N, Bloch M, McNulty A, Denham I, Doong N, Trottier S, Adena M, Bonney MA, Agnew J, Australo-Canadian FaST Famciclovir Short-Course Herpes Therapy Study Group. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sexual health,  2008. 5: 219-25

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Annals of internal medicine,  2008. 149: 289-99